vs
Side-by-side financial comparison of Inogen Inc (INGN) and Syndax Pharmaceuticals Inc (SNDX). Click either name above to swap in a different company.
Inogen Inc is the larger business by last-quarter revenue ($68.6M vs $68.5M, roughly 1.0× Syndax Pharmaceuticals Inc). On growth, Syndax Pharmaceuticals Inc posted the faster year-over-year revenue change (791.7% vs 3.4%).
Inogen Inc is a medical technology firm specializing in the development, production and distribution of portable oxygen concentrators and associated respiratory care products. It caters primarily to patients with chronic respiratory conditions needing long-term oxygen therapy across North America, Europe and other global markets, focusing on home care and ambulatory patient segments to enhance users' quality of life.
Syndax Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing innovative oncology therapies for patients with hard-to-treat cancers. Its pipeline includes targeted and immunotherapy candidates addressing unmet medical needs, primarily serving global oncology healthcare stakeholders and patient populations.
INGN vs SNDX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $68.6M | $68.5M |
| Net Profit | — | $-68.0M |
| Gross Margin | 51.4% | — |
| Operating Margin | -13.6% | -91.3% |
| Net Margin | — | -99.3% |
| Revenue YoY | 3.4% | 791.7% |
| Net Profit YoY | — | 27.8% |
| EPS (diluted) | $-0.26 | $-0.78 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $68.6M | $68.5M | ||
| Q3 25 | $79.1M | $45.9M | ||
| Q2 25 | $79.2M | $38.0M | ||
| Q1 25 | $68.5M | $20.0M | ||
| Q4 24 | $66.3M | — | ||
| Q3 24 | $74.9M | $12.5M | ||
| Q2 24 | $74.4M | — | ||
| Q1 24 | $63.1M | $0 |
| Q4 25 | — | $-68.0M | ||
| Q3 25 | $-5.3M | $-60.7M | ||
| Q2 25 | $-4.2M | $-71.8M | ||
| Q1 25 | $-6.2M | $-84.8M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-6.0M | $-84.1M | ||
| Q2 24 | $-5.6M | — | ||
| Q1 24 | $-14.6M | $-72.4M |
| Q4 25 | 51.4% | — | ||
| Q3 25 | 52.2% | — | ||
| Q2 25 | 52.2% | — | ||
| Q1 25 | 53.1% | — | ||
| Q4 24 | 54.7% | — | ||
| Q3 24 | 55.2% | — | ||
| Q2 24 | 57.4% | — | ||
| Q1 24 | 54.5% | — |
| Q4 25 | -13.6% | -91.3% | ||
| Q3 25 | -9.0% | -125.2% | ||
| Q2 25 | -7.7% | -182.7% | ||
| Q1 25 | -11.2% | -417.9% | ||
| Q4 24 | -17.2% | — | ||
| Q3 24 | -10.4% | -716.6% | ||
| Q2 24 | -9.5% | — | ||
| Q1 24 | -25.8% | — |
| Q4 25 | — | -99.3% | ||
| Q3 25 | -6.7% | -132.4% | ||
| Q2 25 | -5.2% | -189.3% | ||
| Q1 25 | -9.0% | -423.3% | ||
| Q4 24 | — | — | ||
| Q3 24 | -8.0% | -673.0% | ||
| Q2 24 | -7.5% | — | ||
| Q1 24 | -23.1% | — |
| Q4 25 | $-0.26 | $-0.78 | ||
| Q3 25 | $-0.20 | $-0.70 | ||
| Q2 25 | $-0.15 | $-0.83 | ||
| Q1 25 | $-0.25 | $-0.98 | ||
| Q4 24 | $-0.41 | — | ||
| Q3 24 | $-0.25 | $-0.98 | ||
| Q2 24 | $-0.24 | — | ||
| Q1 24 | $-0.62 | $-0.85 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $103.7M | $394.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $192.2M | $64.6M |
| Total Assets | $298.6M | $529.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $103.7M | $394.1M | ||
| Q3 25 | $106.5M | $436.0M | ||
| Q2 25 | $103.7M | $455.2M | ||
| Q1 25 | $118.9M | $512.2M | ||
| Q4 24 | $113.8M | — | ||
| Q3 24 | $105.7M | $389.6M | ||
| Q2 24 | $97.9M | — | ||
| Q1 24 | $107.4M | $434.6M |
| Q4 25 | $192.2M | $64.6M | ||
| Q3 25 | $197.2M | $115.4M | ||
| Q2 25 | $199.5M | $157.4M | ||
| Q1 25 | $198.0M | $215.1M | ||
| Q4 24 | $173.9M | — | ||
| Q3 24 | $185.4M | $366.4M | ||
| Q2 24 | $187.6M | — | ||
| Q1 24 | $191.9M | $491.9M |
| Q4 25 | $298.6M | $529.7M | ||
| Q3 25 | $307.0M | $551.8M | ||
| Q2 25 | $312.0M | $596.1M | ||
| Q1 25 | $308.4M | $640.7M | ||
| Q4 24 | $296.2M | — | ||
| Q3 24 | $306.2M | $425.8M | ||
| Q2 24 | $308.9M | — | ||
| Q1 24 | $315.6M | $543.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-943.0K | $-69.5M |
| Free Cash FlowOCF − Capex | $-1.9M | — |
| FCF MarginFCF / Revenue | -2.8% | — |
| Capex IntensityCapex / Revenue | 1.4% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-13.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-943.0K | $-69.5M | ||
| Q3 25 | $2.2M | $-70.5M | ||
| Q2 25 | $4.3M | $-87.8M | ||
| Q1 25 | $-16.8M | $-95.2M | ||
| Q4 24 | $-3.0M | — | ||
| Q3 24 | $7.0M | $-62.3M | ||
| Q2 24 | $6.7M | — | ||
| Q1 24 | $-4.7M | $-83.5M |
| Q4 25 | $-1.9M | — | ||
| Q3 25 | $1.6M | — | ||
| Q2 25 | $3.7M | — | ||
| Q1 25 | $-17.1M | — | ||
| Q4 24 | $-3.3M | — | ||
| Q3 24 | $5.3M | — | ||
| Q2 24 | $6.6M | — | ||
| Q1 24 | $-6.1M | — |
| Q4 25 | -2.8% | — | ||
| Q3 25 | 2.0% | — | ||
| Q2 25 | 4.6% | — | ||
| Q1 25 | -24.9% | — | ||
| Q4 24 | -5.0% | — | ||
| Q3 24 | 7.1% | — | ||
| Q2 24 | 8.9% | — | ||
| Q1 24 | -9.6% | — |
| Q4 25 | 1.4% | — | ||
| Q3 25 | 0.7% | — | ||
| Q2 25 | 0.9% | — | ||
| Q1 25 | 0.4% | — | ||
| Q4 24 | 0.5% | — | ||
| Q3 24 | 2.2% | — | ||
| Q2 24 | 0.1% | — | ||
| Q1 24 | 2.1% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
INGN
| Other | $36.1M | 53% |
| Non Us | $32.5M | 47% |
SNDX
Segment breakdown not available.
